Following a 15-min fixation in 4% paraformaldehyde, the samples were permeabilized with 0.1% Triton X-100 for 20 min. Each sample underwent treatment with a blocking agent and subsequent incubation with primary antibodies. The primary antibodies used were as follows: anti-CK14 (1:100; Cell Signaling Technology, Danvers, MA, USA), anti-c-Kit (1:400; Cell Signaling Technology), anti-STRO-1 (1:100; R&D Systems, Minneapolis, MN, USA), anti-Vimentin (1:500; Abcam, Cambridge, UK), anti-8-OHdG (1:100; Sigma), anti-collagen I (COL1; 1:100, Abcam), anti-osteopontin (OPN; 1:100, Abcam), and anti-NRF2 (1:100; Cell Signaling Technology). Following the retrieval of the antibodies, DAPI and the appropriate secondary antibody were incubated. Immunofluorescence images were acquired using a confocal microscope.
Anti 8 ohdg
Manufactured by Merck Group
Sourced in United Kingdom
The Anti-8-OHdG is a laboratory equipment product developed by Merck Group. It is a highly specific antibody that recognizes and binds to 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker for oxidative DNA damage. The primary function of this product is to facilitate the detection and quantification of 8-OHdG in various biological samples, allowing researchers to assess levels of oxidative stress and DNA damage.
Automatically generated - may contain errors
Lab products found in correlation
Anti nrf2, by Cell Signaling Technology (2 mentions)
Anti c kit, by Cell Signaling Technology (2 mentions)
Anti vimentin, by Abcam (2 mentions)
Anti collagen 1 col1, by Abcam (2 mentions)
Anti ck14, by Cell Signaling Technology (2 mentions)
Anti stro 1, by R&D Systems (2 mentions)
Anti osteopontin opn, by Abcam (2 mentions)
2 protocols using anti 8 ohdg
1
Comprehensive Immunostaining Protocol for Stem Cell Analysis
2
Comprehensive Immunostaining Protocol for Stem Cell Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Following a 15-min fixation in 4% paraformaldehyde, the samples were permeabilized with 0.1% Triton X-100 for 20 min. Each sample underwent treatment with a blocking agent and subsequent incubation with primary antibodies. The primary antibodies used were as follows: anti-CK14 (1:100; Cell Signaling Technology, Danvers, MA, USA), anti-c-Kit (1:400; Cell Signaling Technology), anti-STRO-1 (1:100; R&D Systems, Minneapolis, MN, USA), anti-Vimentin (1:500; Abcam, Cambridge, UK), anti-8-OHdG (1:100; Sigma), anti-collagen I (COL1; 1:100, Abcam), anti-osteopontin (OPN; 1:100, Abcam), and anti-NRF2 (1:100; Cell Signaling Technology). Following the retrieval of the antibodies, DAPI and the appropriate secondary antibody were incubated. Immunofluorescence images were acquired using a confocal microscope.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!